Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies
Vancouver, Canada, March 17, 2026 -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the publication of six patents by the Intellectual Property Department in Hong Kong. These patents cover proprietary combination therapies integrating Palmitoylethanolamide (
The published patents protect innovative synergistic formulations combining PEA with each of the following:
"We continue to expand our global IP portfolio and taking steps forward in protecting our innovative approach to psychedelic-based combination therapies," said Adi Zuloff-Shani, CEO of Clearmind Medicine. "By strategically combining PEA from our valued partners at NeuroThera with well-characterized psychedelics such as MDMA, LSD, ketamine, ibogaine, psilocybin, and DMT, we continue to build a robust pipeline of next-generation candidates designed to address unmet needs in mental health and beyond.”
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Exchange Traded Funds Top 10 Volume Leaders
NET % VOL STOCK (Symbol) LAST CHG CHG 100s Direxion Semicon Br 3x SOXS 33.79 3.14 10.24 113,576,607 ProShares Bitcoin ETF BITO 10.93 -0.21 -1.89 112,012,221 Direxion Semicon Bl 3x SOXL 142.52 -16.39 -10.31 100,351,229 ProShares Sh Russell2001 RWM 14.43 0.01 0.07 77,482,048 GrShr 2x Sh NVDA Daily NVD 3.55 0.20 5.97 73,813,301 ProShares UltraPro QQQ TQQQ 80.23 -3.39 -4.05 65,485,124 ProSh UltraPro Shrt QQQ SQQQ 33.37 1.30 4.05 60,470,210 iShares Bitcoin Trust ETF IBIT 46.26 -0.95 -2.01 56,191,237 Direxion PLTR Bear 1X PLTD 4.50 -0.11 -2.39 52,552,250 SS Energy Sel SPDR XLE 65.24 1.88 2.97 50,492,628 (END) Dow Jones Newswires October 08, 2026 17:38 ET (21:38 GMT)
--Zoetis Keeps Quarterly Dividend at $0.53 a Share, Payable Dec. 1 to Holders of Record Oct. 30
04:46 PM EDT, 10/08/2026 (MT Newswires) -- Zoetis Keeps Quarterly Dividend at $0.53 a Share, Payable Dec. 1 to Holders of Record Oct. 30
Should You Buy Microsoft Stock (MSFT) in October? 3 Things Investors Need to Know
U.S. Fed weekly balance sheet
Oct 8 (Reuters) - For details of the Federal Reserve's balance sheet, see the following link: http://www.federalreserve.gov/releases/h41/Current/h41.pdf ((Washington newsroom))
Crypto prices
More
